ReviewJournal of perinatology : official journal of the California Perinatal Association2026
Toward precision for bronchopulmonary dysplasia: Moving past current definitions.
Review in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Candidate Salivary miRNA Panel for Bronchopulmonary Dysplasia in Very and Extremely Low-Birth-Weight Preterm Infants: A Pilot Exploratory Study.Life (Basel, Switzerland) · 2026Article
- Predicting bronchopulmonary dysplasia is complicated (as it should be): toward a framework for integrating physiological data.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bronchopulmonary dysplasia (BPD) remains a prevalent and complex complication of preterm birth, yet current definitions fail to capture the heterogeneous and evolving nature of the disease. Longitudinal studies reveal persistent pulmonary disease throughout the lifespan. Despite progress in identifying phenotypes, biomarkers to characterize disease endotypes to guide effective and precise therapies remain elusive. Precision medicine approaches, including multicenter deep phenotyping and integration of multi-omic data, are essential to identify meaningful disease subtypes that inform individualized care. This perspective traces the evolution of BPD definitions, outlines their limitations, and presents a path forward focused on collaborative data networks, enriched trial designs, and longitudinal outcome measures. Recognizing BPD and subsequent cardiopulmonary disease related to prematurity as a lifelong disease, not just a NICU outcome, is critical to improving long-term care and developing targeted interventions for this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.